An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.

被引：1

作者：

Decoster, Lore

Cappoen, Nadia

Aftimos, Philippe Georges

Raicevic, Gordana

Rolfo, Christian Diego

Rottey, Sylvie

Duhoux, Francois P.

Collignon, Joelle

Hebrant, Aline

Vandenbulcke, Marc

De Greve, Jacques

机构：

[1] UZ Brussel, Brussels, Belgium

[2] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium

[3] Belgian Soc Med Oncol, Brussels, Belgium

[4] Univ Antwerp Hosp, Edegem, Belgium

[5] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium

[6] Clin Univ St Luc, King Albert II Canc Inst, Dept Med Oncol, Brussels, Belgium

[7] Catholic Univ Louvain, Inst Rech Expt & Clin Pole MIRO, Brussels, Belgium

[8] CHU Sart Tilman, Liege, Belgium

[9] Wetenschappelijk Inst Volksgezondheid Belgie, Brussels, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS2615

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS2615

引用

页数：1

共 50 条

[21] Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
Rastislav Bahleda
Andrea Varga
Yann Bergé
Jean-Charles Soria
David Schnell
Inga Tschoepe
Martina Uttenreuther-Fischer
Jean-Pierre Delord
British Journal of Cancer, 2018, 118 : 344 - 352
[22] Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
Bahleda, Rastislav
Varga, Andrea
Berge, Yann
Soria, Jean-Charles
Schnell, David
Tschoepe, Inga
Uttenreuther-Fischer, Martina
Delord, Jean-Pierre
BRITISH JOURNAL OF CANCER, 2018, 118 (03) : 344 - 352
[23] Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
Harding, James J.
Piha-Paul, Sarina Anne
Shah, Ronak H.
Cleary, James M.
Quinn, David I.
Brana, Irene
Moreno, Victor
Borad, Mitesh J.
Loi, Sherene
Spanggaard, Iben
Ford, James M.
DiPrimeo, Daniel
Berger, Michael F.
Eli, Lisa DeFazio
Meric-Bernstam, Funda
Solit, David B.
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
Richards, Donald A.
Braiteh, Fadi S.
Garcia, A. A.
Denlinger, Crystal Shereen
Conkling, Paul R.
Edenfield, William Jeffery
Anthony, Stephen Patrick
Hellerstedt, Beth A.
Raju, Robert N.
Becerra, Carlos
Harb, Wael A.
Smith, David A.
McDonagh, Charlotte Fenton
Kawash, Kate-Lyn
Frye, Sasha
Moyo, Victor M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[25] Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
Schram, Alison M.
Goto, Koichi
Kim, Dong-Wan
Martin-Romano, Patricia
Ou, Sai-Hong Ignatius
O'Kane, Grainne M.
O'Reilly, Eileen Mary
Umemoto, Kumiko
Duruisseaux, Michael
Neuzillet, Cindy
Opdam, Frans
Ahnert, Jordi Rodon
Nagasaka, Misako
Weinberg, Benjamin Adam
Macarulla, Teresa
Joe, Andrew K.
Ford, Jim
Stalbovskaya, Viktoriya
Wasserman, Ernesto
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
Hyman, David M.
Piha-Paul, Sarina A.
Rodon, Jordi
Saura, Cristina
Shapiro, Geoffrey I.
Quinn, David I.
Moreno, Victor
Mayer, Ingrid A.
Arteaga, Carlos
Boni, Valentina
Calvo, Emiliano
Loi, Sherene
Lockhart, Albert C.
Smyth, Lillian M.
Erinjeri, Joseph
Scaltriti, Maurizio
Ulaner, Gary
Torrisi, Jean
Patel, Juber
Tang, Jiabin
Meng, Fanli
Selcuklu, Duygu
Won, Helen
Bouvier, Nancy
Berger, Michael F.
Cutler, Richard E.
Xu, Feng
Butturini, Anna
Eli, Lisa D.
Mann, Grace
Lalani, Alshad S.
Bryce, Richard P.
Meric-Bernstam, Funda
Baselga, Jose
Solit, David B.
CANCER RESEARCH, 2017, 77
[27] Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
Yap, Timothy A.
Vidal, Laura
Adam, Jan
Stephens, Peter
Spicer, James
Shaw, Heather
Ang, Jooern
Temple, Graham
Bell, Susan
Shahidi, Mehdi
Uttenreuther-Fischer, Martina
Stopfer, Peter
Futreal, Andrew
Calvert, Hilary
de Bono, Johann S.
Plummer, Ruth
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3965 - 3972
[28] Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-na⟨ve advanced breast cancer
Johnston, Stephen
Basik, Mark
Hegg, Roberto
Lausoontornsiri, Wirote
Grzeda, Lukasz
Clemons, Mark
Dreosti, Lydia
Mann, Helen
Stuart, Mary
Cristofanilli, Massimo
BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (01) : 91 - 99
[29] Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer
Stephen Johnston
Mark Basik
Roberto Hegg
Wirote Lausoontornsiri
Lukasz Grzeda
Mark Clemons
Lydia Dreosti
Helen Mann
Mary Stuart
Massimo Cristofanilli
Breast Cancer Research and Treatment, 2016, 160 : 91 - 99
[30] A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
Richards, Donald A.
Braiteh, Fadi S.
Anthony, Stephen Patrick
Edenfield, Jeff
Hellerstedt, Beth A.
Raju, Robert N.
Conkling, Paul
Smith, David A.
Becerra, Carlos
Cohn, Allen Lee
Denlinger, Crystal Shereen
Garbo, Lawrence E.
Wu, Hillary H.
Garcia, Agustin
McDonagh, Charlotte
Frye, Sasha
Agresta, Samuel V.
Moyo, Victor M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →